{
  "meta": {
    "title": "11_Carcinoma_Breast_-_Treatment",
    "url": "https://brainandscalpel.vercel.app/11-carcinoma-breast-treatment-50964d71.html",
    "scrapedAt": "2025-11-30T12:35:47.472Z"
  },
  "questions": [
    {
      "text": "What procedure is depicted in the image?",
      "choices": [
        {
          "id": 1,
          "text": "Brachytherapy"
        },
        {
          "id": 2,
          "text": "Lateral pectoral block"
        },
        {
          "id": 3,
          "text": "USG-guided biopsy"
        },
        {
          "id": 4,
          "text": "Sentinel lymph node biopsy"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The image shows a <strong>sentinel lymph node biopsy </strong>using a gamma camera.</p>\n<p>The sentinel lymph node is the <strong>first draining lymph node</strong>.&nbsp;SLNB was first described in <strong>penile cancer</strong> by <strong>Cabana</strong>.&nbsp;Sentinel lymph node biopsy is only done&nbsp;on <strong>node-negative tumors</strong>.</p>\n<p><strong>Methylene blue dye</strong> or radioisotope i.e.,<strong>&nbsp;technetium-labeled albumin</strong> is injected into breast tissue (or subdermal tissue) at the site of the primary tumor or at the subareolar position. The sentinel node is identified as a <strong>blue node</strong> or as a <strong>radioactive node</strong> (using a gamma camera).&nbsp;The frozen section biopsy is sent to the pathologist for identification of cancer cells. If the <strong>biopsy is positive</strong> for cancer cells, then <strong>axillary dissection</strong> is simultaneously performed.&nbsp;</p>\n<p>Note: The combination of blue dye and technetium-labeled colloid has been reported to improve the detection of sentinel lymph nodes.&nbsp;Newer techniques involve the use of a fluorescent or magnetic tracer instead of the radiolabelled dye.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/bcefb7f9537e4de286250de486df9ef1x1280x3063.JPEG\" alt=\"Explanation Image\">",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/1080a0881c734743b8e4dce7f556b55a.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7094",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is true regarding sentinel lymph node biopsy in a patient with a T2 N1 M0 breast tumour?",
      "choices": [
        {
          "id": 1,
          "text": "If biopsy is positive, then axillary dissection is not done"
        },
        {
          "id": 2,
          "text": "If biopsy is negative, then axillary dissection is done"
        },
        {
          "id": 3,
          "text": "If biopsy is positive then tumour free margin should be > 2 cm"
        },
        {
          "id": 4,
          "text": "It is not indicated"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Sentinel lymph node biopsy is only done in&nbsp;<strong>node-negative</strong> tumors. It is<strong> not</strong> done in<strong> N1</strong> stage tumors.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0130",
      "difficulty": "hard"
    },
    {
      "text": "A 40-year-old woman presents with a lump in her right breast. On examination, a 3 cm palpable mass is felt in the right upper quadrant of the right breast. A mammogram is suggestive of a malignant lesion. Biopsy confirmed invasive ductal carcinoma with no nodal involvement. How will you manage this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Modified radical mastectomy"
        },
        {
          "id": 2,
          "text": "Adjuvant chemotherapy with mastectomy"
        },
        {
          "id": 3,
          "text": "Breast conservation therapy with adjuvant radiotherapy"
        },
        {
          "id": 4,
          "text": "Modified radical mastectomy with adjuvant radiotherapy"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>This patient has <strong>stage</strong>&nbsp;<strong>T2 breast carcinoma</strong>. These patients are managed with <strong>breast conservation therapy with adjuvant radiotherapy.</strong></p>\n<p><strong>Indications</strong> of breast conservation surgery <strong>(BCS):</strong></p>\n<ol>\n<li aria-level=\"1\">DCIS/Tis tumors</li>\n<li aria-level=\"1\">T1-2 tumors</li>\n<li aria-level=\"1\">No contraindication for adjuvant radiotherapy</li>\n<li aria-level=\"1\">Excision with clear margins is possible</li>\n<li aria-level=\"1\">Who does not want a mastectomy</li>\n<li aria-level=\"1\">Locally advanced tumors with excellent response to neoadjuvant chemotherapy.</li>\n</ol><hr><h3>Related Pearl: TNM Staging of Carcinoma Breast</h3><table>\n<tbody>\n<tr>\n<td><strong>Tumor (T)</strong></td>\n<td>\n<p><strong>Description</strong></p>\n</td>\n</tr>\n<tr>\n<td>Tx</td>\n<td>\n<p>Primary tumor cannot be assessed</p>\n</td>\n</tr>\n<tr>\n<td>T0</td>\n<td>\n<p>No evidence of primary tumor</p>\n</td>\n</tr>\n<tr>\n<td><strong>Tis (DCIS)</strong></td>\n<td>Ductal carcinoma in situ</td>\n</tr>\n<tr>\n<td><strong>Tis (Paget)</strong></td>\n<td>Paget disease not associated with invasive carcinoma or DCIS</td>\n</tr>\n<tr>\n<td>T1</td>\n<td>\n<p><strong>&le;</strong><strong>2 cm</strong> in greatest dimension</p>\n<p><strong>1mic</strong>&nbsp;&le; 0.1 cm</p>\n<p>1a &gt;0.1 to 0.5 cm</p>\n<p>1b &gt;0.5 to 1 cm</p>\n<p>1c &gt;1 to 2 cm</p>\n</td>\n</tr>\n<tr>\n<td>T2</td>\n<td><strong>&gt;2 but &le;5 cm</strong> in greatest dimension</td>\n</tr>\n<tr>\n<td>T3</td>\n<td><strong>&gt;5 cm</strong> in greatest dimension</td>\n</tr>\n<tr>\n<td>T4</td>\n<td>\n<p>Tumor of<strong> any size&nbsp;</strong>and -</p>\n<p><strong>4a</strong> &ndash; chest wall involvement (except pectoralis major)<strong>#</strong>&nbsp;</p>\n<p><strong>4b </strong>&ndash; skin involvement in the form of ulceration, peau d&rsquo;orange, satellite nodules &nbsp;</p>\n<p><strong>4c </strong>&ndash; 4a + 4b &nbsp;</p>\n<p><strong>4d</strong> &ndash; Inflammatory breast carcinoma (typical skin changes involving <span>&gt;</span>1/3rd of breast)<strong>*</strong></p>\n</td>\n</tr>\n<tr>\n<td><strong>Nodes (N)</strong></td>\n<td><strong>Description</strong></td>\n</tr>\n<tr>\n<td>N1 mic</td>\n<td>Refers to micrometastasis to Lymph node</td>\n</tr>\n<tr>\n<td>N1</td>\n<td>Ipsilateral <strong>mobile</strong> axillary lymph nodes</td>\n</tr>\n<tr>\n<td>N2A</td>\n<td>Ipsilateral<strong> fixed or matted</strong> axillary lymph nodes</td>\n</tr>\n<tr>\n<td>N2B</td>\n<td>Ipsilateral internal mammary <strong>without axillary lymph node</strong> involvement</td>\n</tr>\n<tr>\n<td>N3A</td>\n<td>Ipsilateral infraclavicular lymph nodes</td>\n</tr>\n<tr>\n<td>N3B</td>\n<td>Ipsilateral internal mammary and axillary lymph nodes</td>\n</tr>\n<tr>\n<td>N3C</td>\n<td>Ipsilateral supraclavicular lymph nodes</td>\n</tr>\n<tr>\n<td><strong>Distant metastasis (M)</strong></td>\n<td><strong>Description</strong></td>\n</tr>\n<tr>\n<td>M0</td>\n<td>Metastasis absent</td>\n</tr>\n<tr>\n<td>M1</td>\n<td>Metastasis present</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Stages</strong></td>\n<td><strong>T, N</strong></td>\n<td>&nbsp;<strong>M</strong></td>\n</tr>\n<tr>\n<td>Stage 0</td>\n<td>T<sub>is</sub>N<sub>0</sub></td>\n<td>M<sub>0</sub></td>\n</tr>\n<tr>\n<td>Stage IA</td>\n<td>T<sub>1</sub>N<sub>0</sub></td>\n<td>M<sub>0</sub></td>\n</tr>\n<tr>\n<td>Stage IB</td>\n<td>T<sub>0,1</sub>N<sub>1mic</sub></td>\n<td>M<sub>0</sub></td>\n</tr>\n<tr>\n<td>Stage IIA</td>\n<td>T<sub>0,1</sub>N<sub>1</sub> (or) T<sub>2</sub>N<sub>0</sub></td>\n<td>M<sub>0</sub></td>\n</tr>\n<tr>\n<td>Stage IIB</td>\n<td>T<sub>2</sub>N<sub>1</sub> (or) T<sub>3</sub>N<sub>0</sub></td>\n<td>M<sub>0</sub></td>\n</tr>\n<tr>\n<td>Stage IIIA</td>\n<td>T<sub>0,1,2,3</sub>N<sub>2 </sub>(or) T<sub>3</sub>N<sub>1</sub></td>\n<td>M<sub>0</sub></td>\n</tr>\n<tr>\n<td>Stage IIIB</td>\n<td><strong>T</strong><sub><strong>4</strong>&nbsp;</sub>N<sub>0,1,2</sub></td>\n<td>M<sub>0</sub></td>\n</tr>\n<tr>\n<td>Stage IIIC</td>\n<td>\n<p>Any T,<strong> N<sub>3</sub></strong></p>\n</td>\n<td>M<sub>0</sub></td>\n</tr>\n<tr>\n<td>Stage IV</td>\n<td>\n<p>Any T, Any N</p>\n</td>\n<td><strong>M<sub>1</sub></strong></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><strong>#&nbsp;</strong>Chest wall includes Serratus anterior, Intercostal muscles, Ribs.&nbsp;Pectoralis muscle is <strong>not</strong> a part of the chest wall.</p>\n<p><strong>*&nbsp;</strong>Inflammatory breast carcinoma (stage 4d) is characterized by the skin changes of&nbsp;<strong>brawny induration, erythema</strong> with a raised edge, and edema (<strong>peaud&rsquo;orange</strong>) involving <span>&gt;</span>1/3rd of the breast.</p>\n<p>Note: LCIS (lobular carcinoma in situ) is considered a benign condition and not included under Tis.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/2202ec4c95df457eb86eaf658395ea5dx1280x943.JPEG\" alt=\"Pearl Image\"><p>Prefixes for TNM staging:</p>\n<ul>\n<li><strong>c:</strong>&nbsp;clinical staging (e.g. cT1b)</li>\n<li><strong>p:</strong>&nbsp;pathological (histological) staging</li>\n<li><strong>y:</strong>&nbsp;stage following systemic or radiation therapy (either prior to surgery or as a primary treatment)</li>\n<li><strong>r:</strong>&nbsp;staging at the time of retreatment or recurrence for disease progression</li>\n</ul>\n<p>Suffix for TNM staging:</p>\n<ul>\n<li><strong>m:</strong>&nbsp;multiple primary tumours of the same histology in the same organ, e.g. T2(m) or T2(5), the latter meaning that there are five primary tumours</li>\n</ul><hr><h3>Related Pearl: Contraindications for Breast Conservative Surgery</h3><p><strong>Absolute contraindications:</strong></p>\n<ul>\n<li>1st-trimester pregnancy</li>\n<li>Diffuse microcalcifications</li>\n<li>Persistently positive pathologic margin</li>\n<li>Multicentric tumor</li>\n</ul>\n<p><strong>Relative contraindications:</strong></p>\n<ul>\n<li>Connective tissue disorders like systemic lupus erythematosus (SLE),  scleroderma and rheumatoid arthritis</li>\n<li>Large lump-to-breast ratio, i.e., a big lump in small breast</li>\n<li>Lump beneath the nipple-areola complex</li>\n<li>Multifocal tumor</li>\n<li>History of therapeutic radiation exposure to the chest wall</li>\n</ul><p>NOTE : Some authorities do not consider Rheumatoid Arthritis as a relative contraindication as the data on radiation toxicity in RA is sparse.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF4009",
      "difficulty": "medium"
    },
    {
      "text": "Breast conservative surgery can be performed in which of the following patients with breast carcinoma?<div class='question-desc-html'><ol>\n<li>A post-partum woman</li>\n<li>A small breasted woman with a large lump</li>\n<li>A woman with a tumor that has a persistently positive pathologic margin</li>\n<li>A woman with diffuse micro-calcification on a mammogram</li>\n<li>A woman with a history of therapeutic radiation exposure to the chest wall</li>\n</ol></div>",
      "choices": [
        {
          "id": 1,
          "text": "2, 3, 4 and 5"
        },
        {
          "id": 2,
          "text": "1, 3 and 4"
        },
        {
          "id": 3,
          "text": "2 and 3"
        },
        {
          "id": 4,
          "text": "Only 1"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Breast conservation surgery can be done in a post-partum woman.</p>\n<p>Breast cancer diagnosed during the<strong> second or third trimester </strong>can be managed with<strong><strong> breast conservation surgery </strong></strong>followed by <strong><strong>adjuvant chemotherapy. </strong></strong></p>\n<p>For breast cancer diagnosed <strong>late</strong> in the <strong>third trimester,</strong> breast conservation surgery can be performed, deferring<strong> breast irradiation until after delivery.</strong></p>\n<div>Breast cancer diagnosed during the <strong>first trimester</strong> should be treated with <strong>mastectomy</strong>. Breast conservation surgery is contraindicated in the first trimester since post-operative radiotherapy cannot be deferred for a long time and chemotherapy is contraindicated in the first trimester.</div><hr><h3>Related Pearl: Contraindications for Breast Conservative Surgery</h3><p><strong>Absolute contraindications:</strong></p>\n<ul>\n<li>1st-trimester pregnancy</li>\n<li>Diffuse microcalcifications</li>\n<li>Persistently positive pathologic margin</li>\n<li>Multicentric tumor</li>\n</ul>\n<p><strong>Relative contraindications:</strong></p>\n<ul>\n<li>Connective tissue disorders like systemic lupus erythematosus (SLE),  scleroderma and rheumatoid arthritis</li>\n<li>Large lump-to-breast ratio, i.e., a big lump in small breast</li>\n<li>Lump beneath the nipple-areola complex</li>\n<li>Multifocal tumor</li>\n<li>History of therapeutic radiation exposure to the chest wall</li>\n</ul><p>NOTE : Some authorities do not consider Rheumatoid Arthritis as a relative contraindication as the data on radiation toxicity in RA is sparse.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB1009",
      "difficulty": "medium"
    },
    {
      "text": "A patient with early breast carcinoma of stage T3 N0 M0 does not want to undergo mastectomy. What is the next best treatment of choice in her case?",
      "choices": [
        {
          "id": 1,
          "text": "Breast conservation surgery followed by radiation therapy"
        },
        {
          "id": 2,
          "text": "Chemotherapy alone since mastectomy is the only option"
        },
        {
          "id": 3,
          "text": "Neoadjuvant chemotherapy followed by breast conservation surgery"
        },
        {
          "id": 4,
          "text": "Mastectomy only since it is a large operable tumour"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>According to the clinical scenario, <strong>neoadjuvant chemotherapy</strong> followed by breast conservation surgery (<strong>BCS</strong>) is the next best treatment.</p>\n<p>Stage <strong>T3 N0 M0</strong> tumors are lesions of size &gt;5 cm and are considered as <strong>large operable breast cancer (LOBC).</strong> The best management for such tumors is<strong> mastectomy</strong>.</p>\n<p>In case the patient is <strong>not willing</strong> for <strong>mastectomy,</strong> the next best treatment is&nbsp;neoadjuvant chemotherapy&nbsp;to shrink the tumor, followed by&nbsp;breast conservation surgery.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0128",
      "difficulty": "medium"
    },
    {
      "text": "You are assisting in a modified radical mastectomy. Which of the following steps will not be done by the operating surgeon during this procedure?",
      "choices": [
        {
          "id": 1,
          "text": "Removal of pectoralis major muscle"
        },
        {
          "id": 2,
          "text": "Level 2 axillary lymph nodes dissection"
        },
        {
          "id": 3,
          "text": "Removal of nipple-areola complex"
        },
        {
          "id": 4,
          "text": "Removal of pectoral fascia"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>Pectoralis major is not removed in modified radical mastectomy.</p>\n<p><strong>Structures removed in modified radical mastectomy</strong>:</p>\n<ol>\n<li>Whole breast tissue</li>\n<li>The skin over the breast tissue</li>\n<li>Nipple-areola complex</li>\n<li>Pectoral fascia</li>\n<li>Levels I, II, &plusmn; III axillary lymph nodes</li>\n</ol>\n<p>The pectoralis <strong>minor</strong> muscle is either cut (<strong>Patey's, Scanlon's</strong> modification) or retracted (<strong>Auchincloss</strong>).</p><hr><h3>Related Pearl: Important surgeries for breast cancer</h3><ul>\n<li>Tylectomy:&nbsp;Excision of lump</li>\n<li><strong>Breast conservation surgery (BCS)/WLE (wide local excision)</strong>: Tumour removal with a 3D clearance of a 1 mm margin of normal tissue</li>\n<li><strong>Simple mastectomy:</strong>&nbsp;Palpable extent of breast +&nbsp;Nipple&ndash;areola complex + overlying skin.</li>\n<li>Extended simple mastectomy: Simple mastectomy + removal of level I axillary lymph nodes.</li>\n<li>Skin-sparing mastectomy: Mastectomy with breast envelope preservation and nipple-areola complex removal</li>\n<li>Skin+ nipple/areola-sparing mastectomy: Mastectomy with breast envelope and nipple-areola complex preservation</li>\n<li><strong>Total mastectomy:</strong>&nbsp;All breast tissue + Nipple&ndash;areola complex + skin.</li>\n<li><strong>Level I oncoplasty (volume displacement surgery):</strong> Tumour excision with wide margins followed by defect repair via dual-plane mobilisation of the breast parenchyma to maintain shape and symmetry</li>\n<li><strong>Level II oncoplasty (volume replacement surgery):</strong> Skin excision and glandular mobilisation involving &gt;20% resection of breast volume</li>\n<li><strong>Modified radical mastectomy:</strong>&nbsp; Entire breast tissue + Nipple&ndash;areola complex + skin + axillary lymph nodes (levels I + II &plusmn; III) dissection\n<ul>\n<li><strong>Patey&rsquo;s:</strong> Pectoralis minor is removed</li>\n<li><strong>Scanlon&rsquo;s</strong>: Pectoralis minor incised</li>\n<li><strong>Auchincloss</strong>: Pectoralis minor only retracted</li>\n</ul>\n</li>\n<li><strong>Halsted&rsquo;s radical mastectomy:</strong>&nbsp;Entire breast tissue + Nipple&ndash;areola complex + skin + Levels I + II+ III Axillary lymph nodes + Pectoralis major and minor</li>\n<li>Extended radical (Urban) - Halsted&rsquo;s + internal mammary lymph nodes dissection</li>\n<li>Extended radical (Dahl-Iverson) mastectomy: Halsted&rsquo;s + internal mammary and supraclavicular lymph nodes dissection</li>\n<li>Super radical mastectomy: Halsted&rsquo;s + internal mammary, supraclavicular and mediastinal lymph nodes dissection.</li>\n</ul>\n<p>*Dual-plane mobilisation of breast parenchyma: Mobilisation of the dermoglandular plane and plane between breast parenchyma and pectoralis muscle.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB0989",
      "difficulty": "easy"
    },
    {
      "text": "In patients with which of the following features of tumor involvement should you not perform radical mastectomy?",
      "choices": [
        {
          "id": 1,
          "text": "Pectoralis major involvement"
        },
        {
          "id": 2,
          "text": "Distant metastasis"
        },
        {
          "id": 3,
          "text": "Axillary lymph node involvement"
        },
        {
          "id": 4,
          "text": "Inter pectoral lymph node involvement"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>Distant metastasis is a <strong>contraindication</strong> for radical mastectomy.</p>\n<p class=\"p1\">Excision of the breast,&nbsp;the pectoralis major and minor muscles, and all axillary lymph nodes&nbsp;constitute&nbsp;radical mastectomy. It is seldom performed given that it causes&nbsp;<strong>substantial morbidity</strong> due to shoulder joint restriction, pain,&nbsp;significant upper limb lymphedema, and chest wall deformity, with <strong>no survival</strong> advantage when compared to less radical&nbsp;surgery. In the case of distant metastases,&nbsp; less radical surgery is of<strong>&nbsp;no benefit</strong>&nbsp;either.</p><hr><h3>Related Pearl: Indications and contraindications for radical mastectomy</h3><p><strong>Indications:</strong></p>\n<ul>\n<li>Large, bulky tumor involving pectoralis major muscle and fascia.</li>\n<li>Axillary lymph node involvement</li>\n<li>Interpectoral lymph node involvement</li>\n</ul>\n<p><strong>Contraindications:</strong></p>\n<ul>\n<li>Non-palpable or small tumors</li>\n<li>Advanced disease with distant metastasis</li>\n<li>Patients who need improved cosmetic result</li>\n<li>Patients who need reconstructive surgery</li>\n<li>Coexisting severe systemic diseases like DM, CHF, CRF</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB1016",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following structures will not be removed while performing radical mastectomy in patients with breast carcinoma?",
      "choices": [
        {
          "id": 1,
          "text": "Pectoralis major"
        },
        {
          "id": 2,
          "text": "Pectoralis minor"
        },
        {
          "id": 3,
          "text": "Axillary lymph nodes"
        },
        {
          "id": 4,
          "text": "Supraclavicular lymph nodes"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Supraclavicular lymph nodes are not removed in radical mastectomy.</p>\n<p>In&nbsp;<strong>Halsted radical mastectomy,&nbsp;</strong>the following structures are&nbsp;removed:</p>\n<ul>\n<li>All breast tissue and skin</li>\n<li>Nipple-areolar complex</li>\n<li><strong>Pectoralis major</strong> and pectoralis minor muscles</li>\n<li>Level I, II, and III axillary lymph nodes.</li>\n</ul><hr><h3>Related Pearl: Important surgeries for breast cancer</h3><ul>\n<li>Tylectomy:&nbsp;Excision of lump</li>\n<li><strong>Breast conservation surgery (BCS)/WLE (wide local excision)</strong>: Tumour removal with a 3D clearance of a 1 mm margin of normal tissue</li>\n<li><strong>Simple mastectomy:</strong>&nbsp;Palpable extent of breast +&nbsp;Nipple&ndash;areola complex + overlying skin.</li>\n<li>Extended simple mastectomy: Simple mastectomy + removal of level I axillary lymph nodes.</li>\n<li>Skin-sparing mastectomy: Mastectomy with breast envelope preservation and nipple-areola complex removal</li>\n<li>Skin+ nipple/areola-sparing mastectomy: Mastectomy with breast envelope and nipple-areola complex preservation</li>\n<li><strong>Total mastectomy:</strong>&nbsp;All breast tissue + Nipple&ndash;areola complex + skin.</li>\n<li><strong>Level I oncoplasty (volume displacement surgery):</strong> Tumour excision with wide margins followed by defect repair via dual-plane mobilisation of the breast parenchyma to maintain shape and symmetry</li>\n<li><strong>Level II oncoplasty (volume replacement surgery):</strong> Skin excision and glandular mobilisation involving &gt;20% resection of breast volume</li>\n<li><strong>Modified radical mastectomy:</strong>&nbsp; Entire breast tissue + Nipple&ndash;areola complex + skin + axillary lymph nodes (levels I + II &plusmn; III) dissection\n<ul>\n<li><strong>Patey&rsquo;s:</strong> Pectoralis minor is removed</li>\n<li><strong>Scanlon&rsquo;s</strong>: Pectoralis minor incised</li>\n<li><strong>Auchincloss</strong>: Pectoralis minor only retracted</li>\n</ul>\n</li>\n<li><strong>Halsted&rsquo;s radical mastectomy:</strong>&nbsp;Entire breast tissue + Nipple&ndash;areola complex + skin + Levels I + II+ III Axillary lymph nodes + Pectoralis major and minor</li>\n<li>Extended radical (Urban) - Halsted&rsquo;s + internal mammary lymph nodes dissection</li>\n<li>Extended radical (Dahl-Iverson) mastectomy: Halsted&rsquo;s + internal mammary and supraclavicular lymph nodes dissection</li>\n<li>Super radical mastectomy: Halsted&rsquo;s + internal mammary, supraclavicular and mediastinal lymph nodes dissection.</li>\n</ul>\n<p>*Dual-plane mobilisation of breast parenchyma: Mobilisation of the dermoglandular plane and plane between breast parenchyma and pectoralis muscle.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB0997",
      "difficulty": "medium"
    },
    {
      "text": "A 50-year-old patient underwent a modified radical mastectomy for breast cancer. A drain was inserted at the site of the surgery. When can the drain be removed?",
      "choices": [
        {
          "id": 1,
          "text": "24 hr output <100 cc"
        },
        {
          "id": 2,
          "text": "Output <100 cc for 2 consecutive days"
        },
        {
          "id": 3,
          "text": "24 hr output <30-40 cc"
        },
        {
          "id": 4,
          "text": "Output <30-40 cc for 2 consecutive days"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The <strong>drain</strong> after <strong>mastectomy</strong> is <strong>removed</strong> when the <strong>output</strong>&nbsp;is <strong>&lt;30-40 cc for 2 consecutive days.&nbsp;</strong></p>\n<p>The closed system suction drains are put in to <strong>prevent</strong> the formation of <strong>seroma.&nbsp;</strong>It&nbsp;is the <strong>most common complication</strong> of mastectomy and axillary lymph node dissection.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF4011",
      "difficulty": "medium"
    },
    {
      "text": "The following image shows the boundaries of axillary lymph node dissection. The inferior boundary marked as ‘A’ denotes _____.",
      "choices": [
        {
          "id": 1,
          "text": "Axillary vein"
        },
        {
          "id": 2,
          "text": "Thoracodorsal pedicle"
        },
        {
          "id": 3,
          "text": "Angular vein"
        },
        {
          "id": 4,
          "text": "Costococlavicular ligament"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The space of axillary lymph node dissection is <strong>inferiorly</strong>&nbsp;bounded by the <strong>angular vein</strong> (marked as &lsquo;A&rsquo;).</p>\n<p><strong>Boundaries</strong> of axillary lymph node dissection (ALND):</p>\n<ul>\n<li>Superior - Axillary vein</li>\n<li>Lateral - Thoracodorsal pedicle</li>\n<li>Medial - Costoclavicular ligament (Halstead ligament)</li>\n<li>Inferior - Angular vein &nbsp; &nbsp;</li>\n</ul>\n<p><strong>Indications</strong> for ALND:</p>\n<ol>\n<li>Locally advanced (T4a, b, c) or inflammatory breast cancer</li>\n<li>Metastatic disease in axillary lymph node(s) proven by needle biopsy, clinically palpable or nonpalpable nodes which are abnormal on imaging</li>\n</ol>\n<p><strong>Structures preserved</strong> during ALND:</p>\n<ol>\n<li>Lateral and medial pectoral nerves</li>\n<li>Thoracodorsal pedicle</li>\n</ol><img src=\"https://cdn1.dailyrounds.org/uploads/f9b7d5fc60a14520a7c43badeb6fe232x639x628.JPEG\" alt=\"Explanation Image\">",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/6205455158c644d6bfdb944379a58d04.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0129",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is the most common complication of mastectomy?",
      "choices": [
        {
          "id": 1,
          "text": "Seroma"
        },
        {
          "id": 2,
          "text": "Lymphedema"
        },
        {
          "id": 3,
          "text": "Intercostobrachial nerve damage"
        },
        {
          "id": 4,
          "text": "Wound infection"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The most common complication post-mastectomy is&nbsp;the&nbsp;development of a<strong> seroma</strong>.&nbsp;</p>\n<p>Seroma is a collection of fluid in a surgically created cavity, that results from the <strong>transection</strong> of <strong>vessels and lymphatics</strong>.&nbsp;It&nbsp;presents as a localized, well-circumscribed swelling with discomfort. The fluid is clear, yellow, and viscous.</p>\n<p>Placement of&nbsp;<strong>closed suction drains</strong> that obliterate the space between the pectoralis major and skin flap is used to <strong>prevent </strong>seromas.</p>\n<p>Other complications include:</p>\n<ol>\n<li>Wound infection</li>\n<li>Skin flap breakdown or necrosis</li>\n<li>Lymphedema</li>\n<li>Hemorrhage</li>\n</ol>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB1037",
      "difficulty": "medium"
    },
    {
      "text": "After modified radical mastectomy, a patient complained of loss of sensation over the medial aspect of the right upper arm. The nerve most likely damaged is ______.",
      "choices": [
        {
          "id": 1,
          "text": "Intercostobrachial nerve"
        },
        {
          "id": 2,
          "text": "Axillary nerve"
        },
        {
          "id": 3,
          "text": "Medial cutaneous nerve of arm"
        },
        {
          "id": 4,
          "text": "Long thoracic nerve"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>Resection of the <strong>intercostobrachial nerve</strong>&nbsp;(ICBN) causes loss of sensation over the medial aspect of the upper arm. The intercostobrachial nerve is the lateral cutaneous branch of the second intercostal nerve.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/b9fe4aa2edc94b96befa579f249d80c0x1280x1683.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB1039",
      "difficulty": "easy"
    },
    {
      "text": "A patient underwent surgery for breast carcinoma. She now presents with painless swelling involving the arm as shown in the image below. What is the most likely diagnosis?",
      "choices": [
        {
          "id": 1,
          "text": "Lymphedema"
        },
        {
          "id": 2,
          "text": "Lymphangiosarcoma"
        },
        {
          "id": 3,
          "text": "Venous thrombosis"
        },
        {
          "id": 4,
          "text": "Cellulitis"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The generalized swelling of the left arm of the patient post-surgery for breast carcinoma is suggestive of <strong>post-mastectomy</strong>&nbsp;<strong>lymphedema.</strong></p>\n<p>Lymphoedema occurs when interstitial fluid accumulates due to defective lymphatic drainage. It is a common complication of breast cancer treatment, involving <strong>axillary lymph node dissection</strong>&nbsp;and <strong>radiotherapy.</strong><strong>&nbsp;Sentinel lymph node dissection</strong> (SLND) reduces the risk of lymphedema significantly.</p>\n<p>Clinical signs and symptoms are observed in the <strong>ipsilateral arm.</strong>&nbsp;A significant increase in limb size due to swelling is seen. Other symptoms are&nbsp;heaviness, tightness, numbness, tingling, limb fatigue, and reduced limb mobility.</p>\n<p><strong>Diagnosis</strong> is predominantly based on the clinical swelling of the arm. The girth of the affected arm &gt;2 centimetres than the normal limb,&nbsp;a 200-mL or more increase in limb volume, or a 5% or greater limb volume change are other diagnostic criteria.</p>\n<p>Management:</p>\n<ol>\n<li><strong>Limb elevation</strong>, <strong>elastic arm stockings</strong>, and<strong> pneumatic compression devices</strong> to reduce swelling.&nbsp;</li>\n<li>Using a <strong>low-pH water-based moisturizer </strong>to prevent dry skin caused by excess fluid accumulation.&nbsp;</li>\n<li><strong>Manual lymphatic drainage</strong> (MLD) by a therapist followed by <strong>simple lymphatic drainage</strong> (SLD) by the patient daily aids interstitial fluid evacuation.</li>\n<li>Surgical options include <strong>lymphaticovenular anastomosis</strong>, liposuction, and debulking.</li>\n</ol>\n<p>Other options:</p>\n<p>Option B:&nbsp; &nbsp;<strong>Stewart-Treves syndrome</strong>&nbsp;refers to <strong>lymphangiosarcoma</strong> seen in chronic <strong>long-standing</strong> lymphedema following mastectomy (more than 10 years). They present as single/multiple <strong>bluish-red</strong> skin and<strong> subcutaneous nodules.</strong> They can ulcerate and hemorrhage.</p>\n<p>Option C: <strong>Axillary venous thrombosis</strong> or <strong>Paget-Schrotter disease</strong> is seen in patients doing rigorous exercise and in weightlifters. The compression of the subclavian vein at the thoracic outlet causes <strong>p</strong><strong>ainful</strong> swelling of the arm.</p>\n<p>Option D: <strong>Cellulitis </strong>(lymphangitis) is a bacterial infection of the <strong>skin and subcutaneous tissue</strong>. It is characterized by a <strong>painful</strong> area of <strong>erythematous</strong> and <strong>edematous</strong> tissue.</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/67451aee83c247989f7c4d258187fb6b.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF1388",
      "difficulty": "easy"
    },
    {
      "text": "A  patient presented with acute worsening of edema of the left hand, which was present for the past 5 years. Her surgical history was relevant for a radical mastectomy with radiation therapy for left-sided breast carcinoma. On examination, the limb appears as shown below. What is the likely diagnosis in this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Teitze syndrome"
        },
        {
          "id": 2,
          "text": "Stewart-Treves syndrome"
        },
        {
          "id": 3,
          "text": "Rhabdomyosarcoma"
        },
        {
          "id": 4,
          "text": "Milroy's Disease"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The clinical scenario and image are suggestive of&nbsp;<strong>Stewart&ndash;Treves syndrome</strong>.</p>\n<p>The development of <strong>angiosarcoma</strong> after a combination of <strong>postmastectomy lymphedema</strong> and <strong>radiation therapy</strong> is known as Stewart&ndash;Treves syndrome. It can arise de-novo or in association with post-mastectomy lymphedema. It presents with <strong>acute worsening of edema</strong> with subcutaneous nodules which are hemorrhagic or ulcerative.</p>\n<p>Treatment is <strong>preoperative chemotherapy and radiotherapy</strong> followed by <strong>surgical excision</strong> (radical amputation of arm). The prognosis is poor.</p>\n<p>Option A:<strong> Tietze&nbsp;syndrome&nbsp;</strong>is an inflammatory condition characterized by chest pain and swelling of the cartilage around the ribs at the <strong>costochondral junction</strong>.&nbsp;</p>\n<p>Option C: Rhabdomyosarcoma is a rare type of cancer that affects the muscle tissue, mostly in children and adolescents.</p>\n<p>Option D:<strong> Milroy's disease</strong>&nbsp;is a&nbsp;familial disease, caused by <strong>congenital </strong>abnormalities in the&nbsp;<strong>lymphatic system</strong>. Disruption of the normal drainage of lymph leads to fluid accumulation and&nbsp;hypertrophy&nbsp;of soft tissues.&nbsp;</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/c3ae663956f8488a91132a39114d34b9.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB1038",
      "difficulty": "easy"
    },
    {
      "text": "Identify the flap shown in the image used for breast reconstruction.",
      "choices": [
        {
          "id": 1,
          "text": "Deep inferior epigastric perforator flap"
        },
        {
          "id": 2,
          "text": "Transverse rectus abdominis myocutaneous flap"
        },
        {
          "id": 3,
          "text": "Lattisimus dorsi flap"
        },
        {
          "id": 4,
          "text": "External oblique flap"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The image shows a deep inferior epigastric perforator <strong>(DIEP) </strong>flap<strong>. </strong>It<strong>&nbsp;</strong>is a free flap and a variant of TRAM flap where only the <strong>skin and fat&nbsp;</strong>are moved to the chest.</p><p>Transverse rectus abdominis myocutaneous <strong>(TRAM) </strong>flap is either based on the superior or inferior epigastric artery or both (<strong>supercharged TRAM</strong>). In a TRAM flap, the skin, fat, <strong>and rectus muscle </strong>are moved to the chest.&nbsp;</p>\n<p class=\"p1\">If robust DIEA perforators are identified with a good caliber and dissection can be performed without dividing the muscle, a DIEP flap is preferred. Otherwise, if small-caliber perforators are encountered and not aligned over the medial or lateral row, a TRAM flap is performed to ensure flap viability.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/bd753d65292d41a180d9a45f7d268338x1280x1547.JPEG\" alt=\"Explanation Image\"><p>Option C:<strong> Latissimus dorsi (LD) flap</strong> is&nbsp;an axial flap based on the thoracodorsal pedicle.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/0bdd2c61a97a4c168f8f5164048f189ax1280x1041.JPEG\" alt=\"Explanation Image\"><p>DIEP flap, TRAM flap, and LD flap are autogenous tissues used in breast reconstruction.&nbsp;</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/c0276157df47446fbe1dcc083a295b14.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0125",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is the gold standard flap used in breast reconstruction with autogenous tissue?",
      "choices": [
        {
          "id": 1,
          "text": "Deep inferior epigastric perforators flap"
        },
        {
          "id": 2,
          "text": "Latissimus dorsi musculocutaneous flap"
        },
        {
          "id": 3,
          "text": "Transverse rectus abdominis myocutaneous flap"
        },
        {
          "id": 4,
          "text": "Thoracoepigastric flap"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The <strong>gold standard </strong>in breast reconstruction with <strong>autogenous</strong> tissue is the deep inferior epigastric perforator<strong>&nbsp;(DIEP) flap</strong>.</p>\n<p>In DIEP flap, using a microvascular technique<strong>, </strong>only<strong>&nbsp;</strong>subcutaneous fat and skin are taken, and&nbsp;<strong>no muscle is removed.</strong>&nbsp;As the muscle is spared, there is<strong>&nbsp;</strong>a <strong>decreased risk of abdominal wall weakness</strong> and its associated complications.</p>\n<p>Lattismus dorsi flap (<strong>LD flap</strong>) -&nbsp;does not provide the bulk necessary and an <strong>implant</strong>&nbsp;is usually <strong>required.</strong></p>\n<p>Transverse rectus abdominis myocutaneous flap (<strong>TRAM flap</strong>):</p>\n<ul>\n<li>Skin, fat, and <strong>muscle</strong> are moved to the chest.</li>\n<li>It is the&nbsp;<strong>most commonly</strong> used flap.</li>\n<li>It provides <strong>good cosmesis</strong> and bulk. An implant is usually not required.&nbsp;</li>\n<li>Since the rectus abdominis muscle is excised in the procedure, it can lead to <strong>abdominal wall weakness</strong> and <strong>hernias</strong>.</li>\n</ul>\n<p>The easiest type of reconstruction is using a <strong>silicone gel implant </strong>under the <strong>pectoralis major</strong> muscle. Capsular contraction is a dreaded complication of silicone implants.</p>\n<p>In breast reconstruction surgeries, the timing of reconstruction<strong>&nbsp;may be immediate or delayed</strong>. Impediments to immediate reconstruction include insufficient theatre time and a lack of experienced reconstructive surgeons. In addition, if the patient is likely to need post-op radiotherapy, then a delayed reconstruction using a flap often gives better results.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB1041",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following will you not add as part of the chemotherapeutic regime for a patient with breast cancer?<div class='question-desc-html'><ol>\n<li>Cyclophosphamide</li>\n<li>Fludarabine</li>\n<li>Adriamycin</li>\n<li>Paclitaxel</li>\n<li>Vincristine</li>\n</ol></div>",
      "choices": [
        {
          "id": 1,
          "text": "Only 5"
        },
        {
          "id": 2,
          "text": "1, 3 and 4"
        },
        {
          "id": 3,
          "text": "2 and 5"
        },
        {
          "id": 4,
          "text": "3, 4 and 5"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>Fludarabine and vincristine are not used in chemotherapy for carcinoma breast.</p>\n<p>The present chemotherapy regimen used is <strong>ACT regimen</strong>, i.e., adriamycin, cyclophosphamide, and taxane (paclitaxel). It comprises 4 cycles of <strong>AC</strong>&nbsp;followed by 4 cycles of <strong>T.</strong></p>\n<p><strong>Earlier</strong> regimens that are less commonly used currently are as follows:</p>\n<ul>\n<li><strong>CAF</strong> &ndash; Cyclophosphamide, Adriamycin, 5-Fluorouracil</li>\n<li><strong>CMF</strong> &ndash; Cyclophosphamide, Methotrexate, 5-Fluorouracil</li>\n</ul>\n<p><strong>Indications </strong>for chemotherapy in carcinoma breast:</p>\n<ul>\n<li>Lymph nodes positive</li>\n<li>Lymph nodes negative but tumor size of &gt;1 cm</li>\n<li>Lymph nodes negative and tumor size of &gt;0.5 cm with\n<ol>\n<li>Blood vessel/Lymph vessel invasion</li>\n<li>ER/PR &ndash;ve</li>\n<li>Her-2/neu overexpression</li>\n<li>High grade</li>\n</ol>\n</li>\n<li>Triple-negative breast carcinoma</li>\n<li>High recurrence score after Oncotype Dx.</li>\n</ul><p>Sacituzumab Govitecan-hziy, a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate recently approved by the FDA for the treatment of adult patients with metastatic triple-negative breast cancer who have received at least two prior therapies.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB1019",
      "difficulty": "medium"
    },
    {
      "text": "All are aromatase inhibitors used in the treatment of breast cancer except ______.",
      "choices": [
        {
          "id": 1,
          "text": "Letrozole"
        },
        {
          "id": 2,
          "text": "Anastrozole"
        },
        {
          "id": 3,
          "text": "Exemastane"
        },
        {
          "id": 4,
          "text": "Fulvestrant"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Fulvestrant</strong> is a selective estrogen-receptor down regulator (<strong>SERD</strong>).</p>\n<p><strong>Selec&shy;tive aromatase inhibitors</strong> include:</p>\n<ul>\n<li>Anastrozole</li>\n<li>Exemestane</li>\n<li>Letrozole</li>\n</ul>\n<p>They are used for the treatment of breast cancer in <strong>postmenopausal women.&nbsp;</strong>Selec&shy;tive aromatase inhibitors block the conversion of the hormone androstenedione into estrone by <strong>inhibiting</strong><strong>&nbsp;</strong>the <strong>aromatase enzyme</strong>. This is the main mechanism of the production of estrogen in postmenopausal women.</p><hr><h3>Related Pearl: Hormonal therapy in breast carcinoma given for ER/PR-positive cases</h3><p><strong>Role:</strong></p>\n<ul>\n<li>Reduce risk of recurrence</li>\n<li>Reduce risk of contralateral breast cancer</li>\n<li>Reduce risk of progression of in situ to invasive carcinoma</li>\n</ul><table>\n<tbody>\n<tr>\n<td>Selective estrogen- receptor modulator</td>\n<td>Aromatase inhibitors</td>\n<td>Ovarian suppression/ ablation</td>\n</tr>\n<tr>\n<td>\n<ul>\n<li>Tamoxifen</li>\n<li>Raloxifen</li>\n<li>Arzoxifen</li>\n<li>Fenoxifen</li>\n</ul>\n</td>\n<td>\n<ul>\n<li>Anastrazole</li>\n<li>Letrozole</li>\n<li>Exemestane</li>\n</ul>\n</td>\n<td>\n<ul>\n<li>Oophorectomy</li>\n<li>GnRH analogues</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB1022",
      "difficulty": "medium"
    },
    {
      "text": "A woman presented to the OPD with a painless lump in the left breast. Biopsy confirmed the presence of ductal carcinoma. Immunohistochemistry showed ER +ve, PR +ve, and HER2/neu -ve. Which of the following is the latest drug approved for treating this condition?",
      "choices": [
        {
          "id": 1,
          "text": "Herceptin"
        },
        {
          "id": 2,
          "text": "Palbociclib"
        },
        {
          "id": 3,
          "text": "Buparlisib"
        },
        {
          "id": 4,
          "text": "Ipatasertib"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong> Palbociclib</strong> is the newest drug approved for <strong>metastatic</strong>, hormone receptor&ndash;positive, HER-2/neu-negative <strong>breast cancer. </strong></p>\n<p>It is used along with fulvestrant, a selective estrogen-receptor downregulator (SERD) based on the <strong>PALOMA 3 trial.&nbsp;</strong></p><p>The US-FDA has recently approved the drug <strong>ALPELISIB&nbsp;</strong>(PI3K inhibitor) for the treatment of breast cancer in combination with fulvestrant in postmenopausal women.</p><hr><h3>Related Pearl: Newer drugs in chemotherapy for metastatic breast cancer</h3><p>Treatment of metastatic breast cancer by targeting PI3k/AKT/mTOR pathways has led to newer chemotherapeutic drugs, which are as follows:</p>\n<p><strong>Cyclin-dependent kinase 4/6 inhibitor</strong></p>\n<ul>\n<li><strong>Palbociclib:</strong>&nbsp;Approved for use with aromatase inhibitor (Letrozole) or SERD (Fulvestrant)</li>\n<li>Ribociclib: Approved for use with aromatase inhibitor (Letrozole)</li>\n<li>Abemaciclib: Approved for use with SERD (Fulvestrant)</li>\n</ul>\n<p><strong>mTOR pathway inhibitors</strong></p>\n<ul>\n<li><strong>Everolimus:</strong>&nbsp; Approved for treatment of advanced/metastatic hormone receptor&ndash;positive, HER-2-negative breast cancer</li>\n</ul>\n<p><strong>Phophatidyl-inositol 3 kinase (PI3k) inhibitors</strong></p>\n<ul>\n<li><strong>Buparlisib &ndash; </strong>Not approved, but trials are underway for treatment of metastatic breast carcinoma</li>\n</ul>\n<p><strong>AKT (Protein kinase B) inhibitors</strong></p>\n<ul>\n<li><strong>Ipatasertib:</strong>&nbsp;Not approved, but found beneficial for metastatic triple-negative breast cancer&nbsp;<strong>&nbsp;</strong></li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0121",
      "difficulty": "medium"
    },
    {
      "text": "What is the drug used for estrogen dependant breast cancer?",
      "choices": [
        {
          "id": 1,
          "text": "Estrogen"
        },
        {
          "id": 2,
          "text": "Clomiphene citrate"
        },
        {
          "id": 3,
          "text": "Tamoxifen"
        },
        {
          "id": 4,
          "text": "Adriamycin"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Tamoxifen</strong> is a selective estrogen receptor modulator <strong>(SERM)</strong> that is mainly used for<strong> estrogen receptor-positive</strong> breast cancers in <strong>pre-menopausal women</strong>.</p>\n<p>It exhibits selective agonistic and antagonistic activity for ER receptors (ER&alpha; and ER&beta;):</p>\n<ul>\n<li aria-level=\"1\">Agonist activity at the uterus, bone, liver, and pituitary</li>\n<li aria-level=\"1\">Antagonist activity in breast and blood vessels</li>\n</ul>\n<p>Uses:&nbsp;</p>\n<ul>\n<li aria-level=\"1\">Part of the <strong>primary treatment</strong> regimen for estrogen receptor-positive <strong>(ER+) breast cancers</strong> in pre-menopausal women</li>\n<li aria-level=\"1\"><strong>Adjuvant therapy </strong>after <strong>breast conservative surgery</strong> to prevent a recurrence</li>\n<li aria-level=\"1\"><strong>Tamoxifen</strong> also is effective (a 40%&ndash;50% reduction in tumor incidence) in <strong>preventing</strong> ER+ breast cancer in <strong>women at increased risk</strong>.</li>\n</ul>\n<p>Adverse effects:&nbsp;</p>\n<ul>\n<li aria-level=\"1\">Vasomotor symptoms <strong>(hot flashes) </strong>and sweating</li>\n<li aria-level=\"1\"><strong>Endometrial cancer</strong></li>\n<li aria-level=\"1\">Increased risk of <strong>thromboembolic events</strong></li>\n<li aria-level=\"1\"><strong>Fatty liver disease</strong></li>\n</ul><hr><h3>Related Pearl: Hormonal therapy in breast carcinoma given for ER/PR-positive cases</h3><p><strong>Role:</strong></p>\n<ul>\n<li>Reduce risk of recurrence</li>\n<li>Reduce risk of contralateral breast cancer</li>\n<li>Reduce risk of progression of in situ to invasive carcinoma</li>\n</ul><table>\n<tbody>\n<tr>\n<td>Selective estrogen- receptor modulator</td>\n<td>Aromatase inhibitors</td>\n<td>Ovarian suppression/ ablation</td>\n</tr>\n<tr>\n<td>\n<ul>\n<li>Tamoxifen</li>\n<li>Raloxifen</li>\n<li>Arzoxifen</li>\n<li>Fenoxifen</li>\n</ul>\n</td>\n<td>\n<ul>\n<li>Anastrazole</li>\n<li>Letrozole</li>\n<li>Exemestane</li>\n</ul>\n</td>\n<td>\n<ul>\n<li>Oophorectomy</li>\n<li>GnRH analogues</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB1029",
      "difficulty": "easy"
    },
    {
      "text": "A middle-aged woman underwent a trucut biopsy for the suspicion of malignancy on a mammogram. Microscopy showed the presence of invasive breast carcinoma. IHC staining of the tumor is given below. Which of the following drugs will you add along with chemotherapeutic agents for treating this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Tamoxifen"
        },
        {
          "id": 2,
          "text": "Tamoxifen + Trastuzumab"
        },
        {
          "id": 3,
          "text": "Fulvestrant"
        },
        {
          "id": 4,
          "text": "Palbociclib"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The immunohistochemistry staining shown in the above image is ER+, PR+, and HER2+, which is <strong>triple</strong> <strong>positive</strong> or <strong>luminal type B</strong>. <strong>Chemotherapy</strong> along with <strong>endocrine therapy</strong>, and <strong>trastuzumab</strong> is the adjuvant treatment of choice.</p>\n<p>Positive immunohistochemistry staining is indicated by the presence of brown-colored tissue.</p>\n<ul>\n<li>The Estrogen receptor <strong>(ER)</strong> and Progesterone receptor <strong>(PR)</strong> are both <strong>nuclear</strong> receptors, hence, the nucleus is stained brown if positive.</li>\n<li>The human epidermal growth factor receptor type 2<strong> (HER2)</strong> is a membrane receptor, hence the cell <strong>membrane</strong> is stained brown if positive.</li>\n</ul>\n<p>The image below shows positive and negative staining for ER, PR, and HER2.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/65e64b983f5540fc95708285043d0cc5x243x199.JPEG\" alt=\"Explanation Image\"><p>The adjuvant treatment modalities currently in practice include:</p>\n<ul>\n<li><strong>Endocrine treatment</strong> such as tamoxifen or ovarian suppression. It is given for patients with tumors that are hormone receptor-positive (either ER+ or PR+).</li>\n<li><strong>Anti-HER2</strong> therapy with trastuzumab (humanized monoclonal antibody). It is given for patients with tumors that are HER2 overexpressing.</li>\n<li><strong>Chemotherapy</strong> is given for hormone negative, HER2+, and ER+ tumors.</li>\n</ul>\n<p>The table below shows the summary of the adjuvant treatment approach:</p>\n<table>\n<tbody>\n<tr>\n<td>&nbsp;</td>\n<td colspan=\"2\"><strong>Tumor hormone receptor status (ER,PR) </strong></td>\n</tr>\n<tr>\n<td><strong>Tumor HER2/neu status</strong></td>\n<td><strong>Positive</strong></td>\n<td><strong>Negative</strong> &nbsp;</td>\n</tr>\n<tr>\n<td><strong>Positive</strong></td>\n<td>Endocrine therapy + chemotherapy + trastuzumab</td>\n<td>Chemotherapy + trastuzumab</td>\n</tr>\n<tr>\n<td><strong>Negative</strong></td>\n<td>Endocrine therapy &plusmn; chemotherapy</td>\n<td>Chemotherapy</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>Note: <strong>Palbociclib</strong> is used along with hormone therapy in ER +ve, PR +ve, HER2/neu -ve tumors.</p><hr><h3>Related Pearl: Molecular classification of breast cancer</h3><p>&nbsp;</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Molecular subtypes&nbsp;</strong></td>\n<td>\n<p><strong>Receptor status </strong></p>\n</td>\n<td><strong>Histological subtypes</strong></td>\n</tr>\n<tr>\n<td>\n<p><strong>Luminal A type&nbsp;</strong></p>\n<p><strong>(most common,&nbsp;</strong>best prognosis)</p>\n<p>Mutated gene-&nbsp;BRCA 2</p>\n</td>\n<td>\n<p>ER/PR-&nbsp;+ve</p>\n<p>Her2- -ve</p>\n<p><strong>Ki-67-&nbsp;</strong></p>\n<p><strong>&lt;14% (low)</strong></p>\n</td>\n<td>\n<div class=\"page\" title=\"Page 1069\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Lobular carcinoma</p>\n<p>Mucinous carcinoma</p>\n<p>Tubular carcinoma</p>\n<p>Papillary carcinoma</p>\n</div>\n</div>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Luminal B type (HER2/neu negative)</strong></p>\n<p>Mutated gene-&nbsp;BRCA 2&nbsp;</p>\n</td>\n<td>\n<p>ER/PR-&nbsp;+ve</p>\n<p>Her2- -ve</p>\n<p><strong>Ki-67-&nbsp;</strong></p>\n<p><strong>&gt;14% (high)</strong></p>\n</td>\n<td>\n<div class=\"page\" title=\"Page 1064\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Poorly differentiated, lobular-carcinoma</p>\n</div>\n</div>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Luminal B type (HER2 positive)</strong></p>\n</td>\n<td>\n<p>ER/PR-&nbsp;+ve</p>\n<p>Her2- +ve</p>\n<p><strong>Ki-67-&nbsp;</strong></p>\n<p><strong>variable</strong></p>\n</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p><strong>HER2 enriched</strong></p>\n<p>Mutated gene-&nbsp;TP53</p>\n</td>\n<td>\n<p>ER/PR-&nbsp;-ve</p>\n<p>Her2- +ve</p>\n<p><strong>Ki-67-&nbsp;</strong></p>\n<p><strong>High&nbsp;</strong></p>\n</td>\n<td>\n<p>Apocrine carcinoma</p>\n<p>Micro-papillary carcinoma</p>\n<p>&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Basal type&nbsp;</strong><strong>(Triple-negative)</strong></p>\n<p>Mutated gene-&nbsp;BRCA 1</p>\n</td>\n<td>\n<p>ER/PR-&nbsp;-ve</p>\n<p>Her2- -ve</p>\n<p><strong>Ki-67-&nbsp;</strong></p>\n<p><strong>High</strong></p>\n</td>\n<td>\n<div class=\"page\" title=\"Page 1064\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Medullary carcinoma</p>\n<p>Adenoid cystic carcinoma</p>\n<p>Secretory carcinoma</p>\n<p>Metaplastic carcinoma</p>\n</div>\n</div>\n</div>\n</div>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>*Update: <strong>Claudin low-molecular subtype</strong>&nbsp;is a triple-negative breast cancer with low expression of E-cadherin, with a poor prognosis. It is frequently associated with lymphocyte infiltration.</p>\n<p>Almost all breast malignancies are adenocarcinomas and based on the expression of estrogen receptor and HER2 can be divided into three major biologic subgroups:</p>\n<ul>\n<li><strong>ER-positive HER2-negative tumors&nbsp;</strong>(50% to 65% of tumors) &ndash; range from well-differentiated cancers with low proliferative rates and few chromosomal changes to poorly differentiated cancers with high proliferative rates and large numbers of chromosomal rearrangements. All of these cancers express ER.</li>\n<li><strong>HER2-positive cancers - </strong>10% to 20% of tumors, which may either be ER-positive or ER-negative.</li>\n<li><strong>ER-negative, HER2-negative carcinomas&nbsp;</strong>(triple-negative or basal-like)- are characterized by genomic instability, a high proliferative rate, and expression of many proteins typical of myoepithelial cells (e.g., basal keratins).</li>\n</ul>\n<table>\n<tbody>\n<tr>\n<td>\n<p><strong>Defining Features</strong></p>\n</td>\n<td>\n<p><strong>ER-positive, HER2- negative</strong></p>\n&nbsp;&nbsp;</td>\n<td>&nbsp;</td>\n<td>\n<p><strong>HER2- Positive (ER- positive or negative)</strong></p>\n</td>\n<td>\n<p><strong>ER- negative</strong></p>\n<p><strong>HER2- negative</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Frequency</p>\n</td>\n<td>\n<p>~40-55% (Low proliferation)</p>\n</td>\n<td>\n<p>~10% (High proliferation)</p>\n</td>\n<td>\n<p>~20%</p>\n</td>\n<td>\n<p>~15%</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Included special histologic types</p>\n</td>\n<td>\n<p>Well or moderately differentiated lobular, tubular, mucinous</p>\n</td>\n<td>\n<p>Poorly differentiated lobular</p>\n</td>\n<td>\n<p>Some apocrine</p>\n</td>\n<td>\n<p>Medullary, adenoid cystic, secretory, metaplastic</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Typical patient groups</p>\n</td>\n<td>\n<p>Older women, men, cancers detected by mammographic screening</p>\n</td>\n<td>\n<p><em>BRCA2</em> mutation carriers</p>\n</td>\n<td>\n<p>Young women, non-white women, <em>TP53</em> mutation carrier (ER-positive)</p>\n</td>\n<td>\n<p>Young women, <em>BRCA1 </em>mutation carriers, African American and Hispanic women</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/07321cd03fa74168936aef8d9bc7489b.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0124",
      "difficulty": "easy"
    },
    {
      "text": "A 60 yr old woman underwent a simple mastectomy followed by radiation therapy for ER/PR positive breast cancer. Which of the following is the most appropriate drug to be given to her to prevent the recurrence of breast cancer?",
      "choices": [
        {
          "id": 1,
          "text": "No drug is effective to prevent recurrence"
        },
        {
          "id": 2,
          "text": "Tamoxifen"
        },
        {
          "id": 3,
          "text": "Trastuzumab"
        },
        {
          "id": 4,
          "text": "Anastrozole"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Anastrozole</strong> is an <strong>aromatase inhibitor</strong> and it is the drug of choice for the <strong>prevention</strong> of <strong>recurrence</strong> of <strong>ER/PR positive breast cancer</strong> in <strong>post-menopausal women</strong> (usually &gt;50 years). It is given for 10 years.</p>\n<p><strong>Tamoxifen</strong> is a selective estrogen receptor modulator <strong>(SERM)</strong> and it is the drug of choice for preventing recurrence in <strong>pre-menopausal women.</strong> It has an agonistic action on the endometrium, leading to an <strong>increased risk</strong> of <strong>endometrial cancers.</strong> Hence, it is not used in post-menopausal women.</p>\n<p><strong>Trastuzumab</strong> is a her2/neu receptor antagonist. It is given in patients with <strong>her2/neu status positive.</strong> It would not be effective in this patient.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF4010",
      "difficulty": "hard"
    },
    {
      "text": "Which of the following is not true about accelerated partial breast irradiation?",
      "choices": [
        {
          "id": 1,
          "text": "Irradiation is delivered only at the lumpectomy site"
        },
        {
          "id": 2,
          "text": "Only suitable for women older than or equal to 65 years of age"
        },
        {
          "id": 3,
          "text": "It is used for low-risk DCIS patients"
        },
        {
          "id": 4,
          "text": "It is suitable if surgical margins are negative by ≥ 2 mm"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>Accelerated partial breast irradiation (<strong>APBI</strong>)<strong>&nbsp;</strong>is a <strong>localized </strong>form of<strong> radiation</strong> delivered <strong>after lumpectomy</strong> to only the part of the breast where the tumor was removed. According to the updated guidelines, patients of age <strong>greater than or equal to&nbsp;50 years</strong>&nbsp;are considered suitable for APBI.</p>\n<p>Patients of age &lt;40 years are considered&nbsp;<strong>unsuitable</strong>,&nbsp;while those between 40 and 49 years of age are included in the&nbsp;<strong>cautionary</strong> group<strong>.</strong></p>\n<p>According to the recent American Society for Radiation Oncology (ASTRO) guidelines, the following patients are considered suitable for APBI:</p>\n<ul>\n<li>Patients of age <strong>50 years or older</strong></li>\n<li>Patients with <strong>low-risk DCIS</strong>. Low-risk DCIS includes patients satisfying the following criteria-\n<ol>\n<li>Screen-detected disease</li>\n<li>Low to intermediate nuclear grade</li>\n<li><strong>Tumor size &le; 2.5 cm</strong></li>\n<li>Surgical resection with margins negative by &ge; 3mm</li>\n</ol>\n</li>\n<li>Patients with surgical margins negative by &ge; 2mm</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0126",
      "difficulty": "medium"
    },
    {
      "text": "A postmenopausal woman presented with a 4 cm lump in her left breast. Clinical and radiological examination revealed ipsilateral fixed axillary lymph node involvement without distant metastasis. Histopathology confirms invasive breast carcinoma. Immunohistochemistry is positive for ER, PR but negative for HER-2/Neu. What is the best method of management for this patient?<div class='question-desc-html'><ol>\n<li>Neoadjuvant chemotherapy</li>\n<li>Mastectomy&nbsp;</li>\n<li>Radiation therapy</li>\n<li>Trastuzumab</li>\n<li>Letrozole&nbsp;</li>\n</ol></div>",
      "choices": [
        {
          "id": 1,
          "text": "2 and 4"
        },
        {
          "id": 2,
          "text": "2, 3 and 5"
        },
        {
          "id": 3,
          "text": "1, 2,3 and 4"
        },
        {
          "id": 4,
          "text": "1, 2, 3 and 5"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The best method of management in this patient is <strong>neoadjuvant chemotherapy, mastectomy, radiation</strong> therapy, and<strong>&nbsp;letrozole.</strong></p>\n<p>Step 1:&nbsp;Evaluate the TNM staging and stage grouping of the tumor</p>\n<ul>\n<li>Tumor size 4cm - <strong>T2</strong></li>\n<li>Ipsilateral fixed axillary lymph nodes are positive - <strong>N2a</strong></li>\n<li>No distant metastasis - <strong>M0</strong></li>\n</ul>\n<p>T2N2M0 belongs to the stage group IIIA which is considered<strong> locally advanced breast cancer (LABC).</strong> They are treated by neoadjuvant chemotherapy, mastectomy, and radiation therapy.</p>\n<p>Step 2: Evaluate the receptor status</p>\n<p>The immunohistochemistry is positive for estrogen and progesterone receptors. Therefore the patient has to be started with hormonal therapy with drugs like&nbsp;letrozole, anastrozole, tamoxifen etc.</p>\n<p><strong>Trastuzumab / Herceptin</strong> is a HER-2/Neu blocker and as the patient is HER2/Neu negative, it would not be effective.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD3938",
      "difficulty": "medium"
    },
    {
      "text": "A 41-year-old woman underwent treatment for breast cancer of 1.2 X 1 cm with positive axillary nodes. She completed radiotherapy and chemotherapy and is now receiving tamoxifen. How would you follow up this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Annual mammogram"
        },
        {
          "id": 2,
          "text": "Regular checking of LFT once in 6 months"
        },
        {
          "id": 3,
          "text": "Follow-up with tumour markers once in 6 months"
        },
        {
          "id": 4,
          "text": "Yearly bone scans"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>Follow-up of patients after treatment of breast cancer consists of a <strong>physical examination</strong> once in <strong>3-6 months </strong>for the<strong> first 3 years</strong> and an <strong>annual mammogram.</strong></p>\n<p>Mammography is the only imaging modality necessary for follow-up after breast cancer surgery. There is currently no role for tumor markers, serum investigations, or any other imaging studies like bone scans in routine follow-ups.</p>\n<p>Guidelines for <strong>follow-up after primary treatment</strong>:</p>\n<p><strong>Physical examination</strong>: every 3-6 months for the first 3 years, every 6-12 months for years 4 and 5, and annually thereafter.<br /><strong>Mammography</strong>: initially, 6 months after surgery, and thereafter, annually.<br /><strong>Breast self-examination:</strong> Monthly <br /><strong>Pelvic examination</strong>: Annually in patients taking tamoxifen</p><hr><h3>Related Pearl: Breast Cancer Screening</h3><p><strong>Breast Cancer Screening</strong></p>\n<p>Individuals are encouraged to conduct a <strong>risk assessment by 25 years of age</strong>. This helps classify them into <strong>average risk</strong> or <strong>increased risk groups</strong>.</p>\n<p>Recommendations<strong>:</strong>&nbsp;</p>\n<ol>\n<li aria-level=\"1\"><strong>Average-risk</strong>&nbsp;(no known genetic or family history of breast cancer)</li>\n<ul>\n<li aria-level=\"1\">25-39 years of age: clinical breast examination every 1-3 years;&nbsp;</li>\n<li aria-level=\"2\">&ge; 40 years of age: clinical breast examination and mammogram annually</li>\n</ul>\n<li aria-level=\"1\"><strong>High-risk </strong>(positive family or genetic history of breast cancer)</li>\n<ul>\n<li aria-level=\"2\">Consult a healthcare professional&nbsp;every <strong>6-12 months</strong> <strong>after 21 years of age</strong></li>\n<li aria-level=\"2\"><strong>Annual mammogram or MRI</strong> from 25 years of age or 10 years prior to the age at which the youngest family member was diagnosed with breast cancer (whichever is earliest)</li>\n</ul>\n<li aria-level=\"1\"><strong>Asymptomatic women</strong> with <strong>previously treated breast cancer</strong></li>\n<ul>\n<li aria-level=\"2\">Consult a healthcare professional&nbsp;every <strong>6-12 months</strong></li>\n<li aria-level=\"2\"><strong>Annual mammogram</strong></li>\n<li aria-level=\"2\">Annual MRI to be considered</li>\n</ul>\n<li aria-level=\"1\">Mammogram and USG are&nbsp;<strong>not contraindicated</strong> in <strong>pregnant and breastfeeding</strong> women</li>\n</ol>\n<p><strong>High-risk patients</strong> for breast cancer:</p>\n<ol>\n<li aria-level=\"1\">Women (or a first-degree relative) with a known BRCA1 or BRCA2 mutation or TP53 or PTEN genes</li>\n<li aria-level=\"1\">Two first-degree relatives with breast cancers with or without gene mutations</li>\n<li aria-level=\"1\">Women with a history of chest irradiation between the ages of 10 and 30</li>\n<li aria-level=\"1\">Women with previously biopsy-proven breast cancer</li>\n<li aria-level=\"1\">Women with &ge; 20% lifetime risk for breast cancer based on breast cancer risk models</li>\n</ol>\n<p>*According to <strong>NCCN 2022 guidelines</strong></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7590",
      "difficulty": "hard"
    },
    {
      "text": "Post-operative radiotherapy is given in a patient with breast carcinoma mainly to _____.",
      "choices": [
        {
          "id": 1,
          "text": "Prevent metastasis"
        },
        {
          "id": 2,
          "text": "Induce ablation of the remnant cancer tissue"
        },
        {
          "id": 3,
          "text": "Prevent recurrence"
        },
        {
          "id": 4,
          "text": "Induce ablation of the affected nodes"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The main aim of radiotherapy in breast cancer is to <strong>prevent local recurrence</strong>.</p>\n<p>Radiotherapy is mainly given in the following cases:</p>\n<ul>\n<li>Positive lymph nodes</li>\n<li>After breast conservation surgery.</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB1020",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is the most likely site for hematogenous spread in a patient with breast carcinoma?",
      "choices": [
        {
          "id": 1,
          "text": "Lumbar vertebrae"
        },
        {
          "id": 2,
          "text": "Skull"
        },
        {
          "id": 3,
          "text": "Thoracic vertebrae"
        },
        {
          "id": 4,
          "text": "Femur"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Lumbar vertebrae</strong>, followed by the femur and thoracic vertebrae, are the most common sites for <strong>hematogenous spread</strong> of carcinoma breast. Bone metastases in breast cancer are more <strong>osteolytic</strong> than osteoblastic.</p>\n<p>The most common bony sites of blood-borne metastases are as follows:</p>\n<ul>\n<li>Lumbar vertebrae</li>\n<li>Femur</li>\n<li>Thoracic vertebrae</li>\n<li>Ribs</li>\n<li>Skull</li>\n</ul>\n<p>Note: In <strong>prostate</strong> cancer, the&nbsp;bone metastases are more <strong>osteoblastic</strong> than osteolytic.</p><hr><h3>Related Pearl: Types of metastasis(osteoblastic or osteolytic) and their primary:</h3><p><span><strong>Predominantly osteoblastic:</strong></span></p>\n<ul>\n<li><span>Prostate cancer</span></li>\n<li><span>Osteosarcoma&nbsp;</span></li>\n<li><span>Medullary carcinoma thyroid</span></li>\n</ul>\n<p><span><strong>Mixed osteoblastic and osteolytic:</strong></span></p>\n<ul>\n<li><span>Breast cancer(preponderance toward osteolytic)</span></li>\n<li><span>Lymphoma</span></li>\n<li><span>Urothelial carcinoma&nbsp;</span></li>\n<li><span>Lung cancer</span></li>\n</ul>\n<p><span><strong>Predominantly osteolytic:</strong></span></p>\n<ul>\n<li><span>Renal cell carcinoma</span></li>\n<li><span>Multiple myeloma&nbsp;</span></li>\n<li><span>Thyroid carcinoma(except medullary carcinoma thyroid)</span></li>\n<li><span>Gastrointestinal tract carcinoma</span></li>\n<li><span>Malignant melanoma</span></li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB1036",
      "difficulty": "easy"
    },
    {
      "text": "A pregnant woman at 11-weeks of gestational age presents with a painless lump in the upper quadrant of her left breast. Ultrasound and trucut biopsy revealed the presence of invasive ductal carcinoma. What is the next best step in the management of this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Perform immediate breast conservation therapy"
        },
        {
          "id": 2,
          "text": "Perform mastectomy and start chemotherapy immediately after delivery"
        },
        {
          "id": 3,
          "text": "Mastectomy followed by hormonal therapy in the second and third trimester"
        },
        {
          "id": 4,
          "text": "Mastectomy followed by chemotherapy in the second and third trimester"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Mastectomy </strong>followed by <strong>chemotherapy in the second and third trimester</strong> is the best step of management in a pregnant woman diagnosed to have breast cancer in the first trimester. </p>\n<p><strong>Pregnancy-associated breast cancer</strong> is defined as breast cancer that is diagnosed <strong>during</strong> <strong>pregnancy or within 1 year</strong> postpartum. It is the most common non-gy­necologic malignancy associated with pregnancy. Most patients present with a <strong>painless mass</strong> in the breast with or without bloody nipple discharge.</p>\n<p>Diagnosis is done by ultrasonography and tissue biopsy.</p>\n<p>Treatment of breast cancer in pregnancy involves:</p>\n<ul>\n<li><strong>Mastectomy</strong> in any trimester along with <strong>chemotherapy</strong> in the second and third trimesters.</li>\n<li><strong>Radiotherapy </strong>and<strong> hormonal therapies</strong> are absolutely <strong>contraindicated</strong> during pregnancy because of teratogenicity. They can be initiated after delivery. </li>\n<li>Since radiotherapy is a component of <strong>breast conservation therapy</strong>, it is <strong>contraindicated</strong> in the first trimester of pregnancy. However, breast-conserving lumpectomy and axillary lymph node dissection with chemotherapy can be done in the second and third trimesters of pregnancy followed by radiation after delivery.</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB0983",
      "difficulty": "medium"
    },
    {
      "text": "A 45-year-old woman presented with back pain that was worse during the night. After evaluation, she was diagnosed with a recurrence of ER/PR+ breast cancer with bony metastasis. Which of the following would be the first-line treatment for this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Radiotherapy"
        },
        {
          "id": 2,
          "text": "Chemotherapy + Surgery"
        },
        {
          "id": 3,
          "text": "Chemotherapy + Hormonal Therapy"
        },
        {
          "id": 4,
          "text": "Hormonal therapy"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The given patient has <strong>metastatic breast cancer with bony metastasis</strong>. <strong>Hormone</strong> <strong>therapy</strong> is the <strong>first-line treatment</strong> for these patients due to its minimal side effects. It is particularly useful for bony metastasis.</p>\n<p>In <strong>premenopausal</strong> women, <strong>tamoxifen,</strong> and in <strong>post-menopausal</strong> women, <strong>anastrozole</strong> is preferred.&nbsp;</p>\n<p><strong>Chemotherapy</strong> is added to the regimen in the following scenarios:</p>\n<ol>\n<li>Young woman</li>\n<li><strong>Visceral metastasis&nbsp;</strong></li>\n<li>Rapidly growing tumors</li>\n<li>Failure of hormonal therapy</li>\n</ol>\n<p><strong>Surgery</strong> and <strong>radiotherapy</strong> are sometimes added to the regimen for <strong>palliative</strong> <strong>measures</strong>.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF4102",
      "difficulty": "hard"
    }
  ]
}